Compare · DFTX vs MO
DFTX vs MO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Altria Group Inc. (MO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $110.35B, about 18.3x DFTX ($6.03B).
- Over the past year, DFTX is up 356.2% and MO is down 1.4% - DFTX leads by 357.6 points.
- DFTX has hit the wire 15 times in the past 4 weeks while MO has been quiet.
- MO has more recent analyst coverage (21 ratings vs 7 for DFTX).
- Company
- Definium Therapeutics Inc.
- Altria Group Inc.
- Price
- $44.89-1.15%
- $66.08-1.28%
- Market cap
- $6.03B
- $110.35B
- 1M return
- +4.61%
- -8.33%
- 1Y return
- +356.20%
- -1.44%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 15
- 0
- Recent ratings
- 7
- 21
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest MO
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance
- Cadiz Inc. Announces CFO Succession
- BTIG Research initiated coverage on Altria
- Altria to Host Webcast of 2026 Second-Quarter and First-Half Results
- UBS reiterated coverage on Altria with a new price target
- SEC Form 11-K filed by Altria Group Inc.
- SEC Form 11-K filed by Altria Group Inc.
- Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)